



# COVID-19 VACCINES

## ISV VIRTUAL CONGRESS SERIES

1st Congress  
June 22, 2020

### Registration

[www.ISVCongress.org](http://www.ISVCongress.org)

### CONTACT

PHONE:  
1-508-856-6791

EMAIL:  
[Info@ISVCONGRESS.ORG](mailto:Info@ISVCONGRESS.ORG)

### Program June 22, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions  
Chairs: Linda Klavinskis & Shan Lu, ISV

#### **Opening Session (20 min talks + 5 min Q&A)**

##### **Overview, Chair: Shan Lu, ISV**

9:05am Kwok-Yung Yuen, The University of Hong Kong  
Overview of COVID-19

9:30am Nick Jackson, CEPI  
Overview of COVID-19 vaccine development

#### **Scientific Session One (18 min talks + 7 min Q&A)**

##### **Nucleic Acid Vaccines, Chair: Margaret Liu, ISV**

9:55am Kate Broderick, Inovio Pharmaceuticals  
Advantages of a DNA-based Approach to the  
Development of a COVID-19 Vaccine

10:20am Barney Graham (VRC/NIAID/NIH)  
Rapid COVID-19 Vaccine Development Enabled  
by Prototype Pathogen Preparedness

##### **Viral Vector Vaccines, Chair: Linda Klavinskis, ISV**

10:45am Sarah Gilbert, University of Oxford  
Rapid Progress with Development of ChAdOx1  
nCoV-19

11:10am Tao Zhu, CanSino Biological  
Development of Adenovirus Vector based  
COVID-19 Vaccine

#### **Scientific Session Two (25 min panel discussion)**

##### **Challenges for COVID-19 vaccines development**

##### **Moderator: David Weiner, ISV**

11:35am Peter Openshaw, Imperial College London  
Stanley Perlman, University of Iowa  
Stanley Plotkin, VaxConsult

- Are human challenge studies acceptable?
- Safety concerns and suboptimal antibody responses

#### **Wrap up and announcement of 2<sup>nd</sup> ISV Virtual Congress on COVID-19 Vaccines**

12 noon Closing remarks  
Margaret Liu, ISV

The virtual congress will be run by Microsoft Teams.

